Patients with inflammatory bowel disease that is in remission can safely switch from infliximab to CT-P13, an infliximab biosimilar, according to a study funded by Mundipharma, which produces CT-P13, in the Lancet Gastroenterology & Hepatology. "Switching patients from originator infliximab to a biosimilar can reduce costs, but prospective data about pharmacokinetics and potential immunogenicity are scarce," said author Dr. Anne Strik. Strik's team investigated by conducting a 13-site noninferiority trial that included 46 ulcerative colitis patients and 42 Crohn's disease patients and followed them for 16 weeks after the switch from infliximab to CT-P13.
Study: Infliximab biosimilar effective for IBD in remission
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.